Previous

Rigosertib Demonstrates Considerable Efficacy and Safety in the Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa
Next

Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitroDrug Resistance Compared to Nirmatrelvir